NASDAQ · MDXH

MDxHealth SA financials

$0.5200−5.11%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$107.9M$90.0M$70.2M$0.00$22.2M
Gross profit$69.6M$55.1M$43.9M$0.00$10.6M
Gross margin64.5%61.2%62.6%—47.5%
Operating income-$14.4M-$24.7M-$27.3M$0.00-$26.8M
Net income-$33.5M-$38.1M-$43.1M$0.00-$29.0M
Net margin−31.1%−42.3%−61.4%—−130.4%
Diluted EPS$-0.67$-1.16$-1.66$0.00$-2.38
EBITDA-$5.2M-$16.7M-$20.5M$4.9M-$23.8M
Operating cash flow-$2.2M-$18.5M-$21.5M-$34.1M-$22.5M
Free cash flow-$23.0M-$20.3M-$24.2M-$36.9M-$23.4M
Diluted shares50.0M32.9M25.9M—12.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$29.0M$46.8M$22.4M$15.5M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$106.8M$77.7M$36.2M$35.5M
Total assets$148.0M$157.3M$129.1M$119.1M
Total liabilities$160.0M$142.5M$121.9M$109.8M
Shareholders' equity-$12.1M$14.8M$7.2M$9.3M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology